Exploration and discovery of treatment targets for primary biliary cholangitis based on plasma and cerebrospinal fluid proteomics: A multicenter mendelian randomization study.

Abstract excerpt

BACKGROUND: Primary biliary cholangitis (PBC) is a chronic, progressive autoimmune cholestatic liver disease. Current first-line therapy, ursodeoxycholic acid (UDCA), yields suboptimal response rates, leaving many patients at risk of disease progression. Thus, novel therapeutic targets are urgently needed to slow PBC progression. METHODS: We performed two-sample Mendelian randomization (MR) to identify proteins...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to TNFSF15 gene
• Share to Genetic Predisposition to Disease